65715-93-7

Basic information

• Product Name: H-D-PHG-OTBU HCL
• Synonyms: (R)-tert-Butyl 2-aMino-2-phenylacetate;D-Phenylglycine tert-butyl ester hydrochloride;(alphaR)-alpha-Amino-Benzeneacetic Acid 1,1-Dimethylethyl Ester;tert-Butyl (2R)-amino(phenyl)acetate;D-Phenylglycinetert-butyl ester hydrochloride≥ 99% (HPLC);H-D-PHG-OTBU HCL;D-PHENYLGLYCINE-OTBU HCL;D-PHENYLGLYCINE T-BUTYL ESTER HYDROCHLORIDE
• CAS NO: 65715-93-7
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 243.73
• Mol File: 65715-93-7.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 280.2±20.0 °C(Predicted)
• Appearance: /
• Density: 1.056±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 6.66±0.10(Predicted)
• CAS DataBase Reference: H-D-PHG-OTBU HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-PHG-OTBU HCL(65715-93-7)
• EPA Substance Registry System: H-D-PHG-OTBU HCL(65715-93-7)

Safety Data

• Hazardous Substances Data: 65715-93-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 2835-06-5 phenylglycin 
• 115-11-7 isobutene 
• 188591-75-5 Phenyl-(2,2,2-trifluoro-acetylamino)-acetic acid tert-butyl ester 
• 35132-16-2 tert-butyl α-bromo-α-phenylacetate 
• 6850-57-3 2-methoxybenzylamine 
• 7332-98-1 tert-butyl phenylglyoxylate 
• 932-30-9 2-Hydroxybenzylamine 
• 85-87-0 pyridoxamine 
• 89-97-4 2-CHLOROBENZYLAMINE 
• 540-88-5 acetic acid tert-butyl ester 
• 2935-35-5 (S)-2-phenylglycine 
• 53934-77-3 N-benzyloxycarbonyl-L-2-phenylglycine t-butyl ester 
• 1245735-70-9 Fms-Phg-OtBu 
• 875-74-1 (R)-phenylglycine 

Downstream Products

• 76314-24-4 (2S)-H-Azy-Gly-OBzl 
• 73537-60-7 Z-Gly-D-Gly(ph)-OBu^t 
• 142433-42-9 (S)-[(R)-2-((R)-2,2-Dimethyl-4-phenyl-oxazolidin-3-yl)-propionylamino]-phenyl-acetic acid tert-butyl ester 
• 142319-65-1 (S)-[(S)-2-((R)-2,2-Dimethyl-4-phenyl-oxazolidin-3-yl)-propionylamino]-phenyl-acetic acid tert-butyl ester 
• 142433-50-9 (S)-[(R)-2-((S)-2,2-Dimethyl-4-phenyl-oxazolidin-3-yl)-propionylamino]-phenyl-acetic acid tert-butyl ester 
• 142433-51-0 (S)-[(S)-2-((S)-2,2-Dimethyl-4-phenyl-oxazolidin-3-yl)-propionylamino]-phenyl-acetic acid tert-butyl ester 
• 401504-39-0 2-[N-(2-bromobenzyl)]aminophenylacetic acid tert-butyl ester 
• 441764-65-4 (R)-2-{2-[((S)-1-tert-butoxycarbonyl-1-phenylmethyl)amino]ethoxy}-succinic acid dimethyl ester 
• 866947-68-4 (S)-(2-{3-[(S)-2-((S)-2-Cyclohexyl-2-isobutoxycarbonylamino-acetylamino)-pent-4-enoylamino]-2-hydroxy-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 881902-38-1 [2-(3-tert-butoxycarbonylamino-4-cyclopropyl-2-hydroxy-butyrylamino)-acetylamino]-phenyl-acetic acid tert-butyl ester 
• 876291-41-7 {2-[4,5-dichloro-2-(4-fluoro-phenyl)-6-methoxy-1,3-dioxo-indan-2-yl]-ethylamino}-phenyl-acetic acid tert-butyl ester 
• 905928-94-1 C₃₁H₄₇N₅O₈ 
• 881902-45-0 (4S,5S)-5-{3-[(S)-2-({[((S)-tert-Butoxycarbonyl-phenyl-methyl)-carbamoyl]-methyl}-carbamoyl)-1-cyclopropylmethyl-2-hydroxy-ethyl]-1-cyclopropylmethyl-ureidomethyl}-4-cyclohexyl-2,2-dimethyl-oxazolidine-3-carboxylic acid isobutyl ester 
• 1007879-90-4 (R)-tert-butyl 2-(3,3-dimethylureido)-2-phenylacetate 

Relevant articles and documents

Discovery of M3Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease

In this paper, we report the discovery of dual M3 antagonist-PDE4 inhibitor (MAPI) compounds for the inhaled treatment of pulmonary diseases. The identification of dual compounds was enabled by the intuition that the fusion of a PDE4 scaffold derived from our CHF-6001 series with a muscarinic scaffold through a common linking ring could generate compounds active versus both the transmembrane M3 receptor and the intracellular PDE4 enzyme. Two chemical series characterized by two different muscarinic scaffolds were investigated. SAR optimization was aimed at obtaining M3 nanomolar affinity coupled with nanomolar PDE4 inhibition, which translated into anti-bronchospastic efficacy ex vivo (inhibition of rat trachea contraction) and into anti-inflammatory efficacy in vitro (inhibition of TNFα release). Among the best compounds, compound 92a achieved the goal of demonstrating in vivo efficacy and duration of action in both the bronchoconstriction and inflammation assays in rat after intratracheal administration.

Enantioselective Synthesis of Quaternary Δ4- and Δ5-Dehydroprolines Based on a Two-Step Formal [3+2] Cycloaddition of α-Aryl and α-Alkyl Isocyano(thio)acetates with Vinyl Ketones

A divergent synthesis of optically active quaternary Δ4- and Δ5-dehydro prolines is developed based on the first catalytic enantioselective conjugate addition of α-substituted isocyano(thio)acetates to vinyl ketones that is general for both α-aryl and α-alkyl isocyano(thio)acetates. The new tetrasubstituted C?N stereocenter is formed without the need of any metal salt due to a bifunctional tertiary amine/squaramide catalyst, featuring a bulky polyaryl sidearm and an unusually short squaramide diamide H???H interatomic distance in the solid state.

NOVEL COMPOUNDS

Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction.